Latin America Human Insulin Drugs Market Share

Statistics for the 2023 & 2024 Latin America Human Insulin Drugs market share, created by Mordor Intelligence™ Industry Reports. Latin America Human Insulin Drugs share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Market Share of Latin America Human Insulin Drugs Industry

The Latin American Human Insulin Market is highly fragmented, with three major manufacturers having a large market share. In the United States, there are no other players except Novo Nordisk, Sanofi, and Eli Lilly. While in the remaining countries, the manufacturers confine to the other local or region-specific manufacturers. Mergers and acquisitions between the players in the recent past helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim have an alliance in developing and commercializing Basaglar (insulin glargine).

Latin America Human Insulin Drugs Market Leaders

  1. Novo Nordisk

  2. Eli Lilly

  3. Sanofi

  4. Biocon

  5. Pfizer

*Disclaimer: Major Players sorted in no particular order

Latin America Human Insulin Drugs Market Concentration

Latin America Human Insulin Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)